Video
Dr. Muro Discusses Safety Data from Asian XELIRI Project in CRC
Author(s):
Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).
Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).
This multinational, randomized, phase III trial of the combination of capecitabine and irinotecan (XELIRI) evaluated safety with or without bevacizumab (Avastin) versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic CRC.
Results showed that bevacizumab did not change safety profiles in either the XELIRI or FOLFIRI arms. Both were both well tolerated, says Muro, with incidence of toxicities slightly lower in the XELIRI arm at 53.2% compared with 73% in the FOLFIRI arm.
